• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Integer to deal surgical, orthopedics assets to MedPlast for $600m

Integer to deal surgical, orthopedics assets to MedPlast for $600m

May 4, 2018 By Brad Perriello

Integer HoldingsInteger Holdings (NYSE:ITGR) said yesterday that it plans to sell its advanced surgical and orthopedic assets to MedPlast for $600 million in a deal that will double MedPlast’s top line and bolster the balance sheet for Integer, which missed expectations with its first-quarter earnings.

Proceeds from the all-cash deal, expected to close during the third quarter, are slated to be used to pay down debt, Integer president & CEO Joe Dziedzic said in prepared remarks. The deal does not include Frisco, Texas-based Integer’s portable medical line, the companies said.

“After this divestiture and paying down debt with the proceeds, we expect to be a $1.2 billion company with higher margins, increased net earnings, greater returns on invested capital, and significantly lower debt leverage. This increased financial flexibility will enable us to grow our leadership position in our cardio & vascular and cardiac & neuromodulation product lines as we partner with customers to deliver life-changing innovation,” Dziedzic said.

It’s the third buyout in two years for MedPlast, which bought Vention’s medical device manufacturing services division in March 2017 for an undisclosed amount and acquired medical device assembler Coastal Life Technologies three months later. The Tempe, Ariz.-based company said its sales will near the $1 billion mark after the deal, which will also expand its footprint in Europe.

“MedPlast is incredibly excited about the addition of Integer’s AS&O capabilities to our existing platform,” added CEO Brian King. “This acquisition will further broaden our offerings and strengthen our ability to provide our customers with innovative solutions to meet their challenging needs. It also will provide additional scale and new growth opportunities for MedPlast. We are excited to be working with the AS&O team and look forward to collectively growing our company and continuing to deliver outstanding service to our customers.”

Integer’s Q1 earnings miss the mark

Despite swinging to first-quarter black for the three months ended March 30, Integer missed the consensus earnings expectation on Wall Street despite beating the sales forecast there.

Profits were $8.1 million, or 25¢ per share, on sales of $381.7 million during the quarter, compared with losses of -$4.3 million during Q1 2017; sales grew 10.5% during the most recent period.

Adjusted to exclude one-time items, earnings per share were 61¢, 9¢ off the consensus; analysts were looking for revenues of $365.0 million.

“Integer delivered another quarter of high-single-digit sales growth with even stronger net income and cash flow growth, which enabled significant debt repayment during the quarter,” Dziedzic, said in a separate release. “Our current growth trajectory supports our increased sales, profit and cash flow outlook for 2018.

“During our strategic review last year, we identified the opportunity to unlock significant value for Integer shareholders through the divestiture of our AS&O product line to a market leader like MedPlast. The synergies from this combination include increased innovation, manufacturing capability, and scale, which is reflected in the sale price,” he said. “Looking forward, Integer has clear market leadership positions in our remaining product lines, with differentiated technology and increased financial flexibility to invest more aggressively to grow. We are now better positioned to deliver on our objectives of sales growth above the market, profit growth two times sales growth, and to earn a valuation premium.”

Although its outlook does not include the impact of the MedPlast deal, Integer said it expects to report adjusted EPS this year of $3.20 to $3.50 on sales of $1.51 billion to $1.55 billion.

Filed Under: Contract Manufacturing, MassDevice Earnings Roundup, Mergers & Acquisitions, Orthopedics, Surgical, Wall Street Beat Tagged With: integer, MedPlast

More recent news

  • Zimmer Biomet to expand robotic suite with Monogram acquisition
  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy